Therion gets SPA for pancreatic cancer Phase III

Therion (Cambridge, Mass.) received an SPA from the FDA for a Phase III trial of its Panvac-VF to treat metastatic pancreatic cancer in patients refractory to gemcitabine. The study is expected to beg...